As a result, trials have been initiated to explore various combinations of CDK4/6 inhibitors with PI3K inhibitors, immune checkpoint inhibitors, and targeted agents to enhance the efficacy of CDK4/6 inhibitors in breast and non-breast cancers [10,11]. The gene discussed is CDK4; the disease is breast carcinoma.